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Background
Familial adenomatous polyposis (FAP) is a colon cancer
syndrome with a prevalence of 1:10,000. Patients have
100’s to 1000’s of precancerous colonic polyps and
nearly 100% risk of developing colon cancer at an aver-
age age of 39 years in the absence of colon surveillance
and surgery. Mutations in the APC gene lead to FAP as
well as an attenuated form (AFAP) which presents with
variable phenotypic expression, reduced polyp numbers
and reduced cancer risk as compared to FAP. Current
methods for the clinical diagnosis of genetic diseases
most commonly involve analysis of germline DNA.
Germline DNA-based diagnosis can be incomplete, for
example no mutation is found in approximately 20% of
FAP and 50% of AFAP patients. The objective of this
study is to determine a molecular profile of the colonic
epithelia from patients with APC mutations leading to
FAP or AFAP then to use this information to establish a
gene expression signature for diagnosis and for better
understanding of the disease in the primary affected
tissue.
Methods
Fresh normal-appearing colonic epithelia were obtained
as biopsies during endoscopy and immediately placed in
RNA-later, a tissue preservative for RNA integrity. RNA
was extracted using Qiagen RNeasy purification system.
Aglient 44K RNA microarrays were run using mRNA
from FAP patients (n=6), AFAP patients (n=14) and
control patients (n=12). Normalized log ratios for each
sample vs. reference RNA were the input for analysis
using the Rank Product to generate a p-value for signifi-
cance of differential expression and to cluster using
Ward’s Method in the Spotire DecisionSite software.
Results
Analysis using the Rank Product method found
48 mRNA probes with statistical significance (p<0.001)
that consistently distinguish between control, FAP and
AFAP normal appearing colonic tissue. These probes
are up in FAP vs. control but low in AFAP vs. control
or vice versa and will be tested for their accuracy to
classify FAP and AFAP patients. Differential expression
was also evaluated to better understand the phenotypic
variability within AFAP using 5 individuals with> 100
adenomas versus 6 individuals with < 20 adenomas with
the identical APC mutation. Differential expression
identified 245 probes with a p-value of <0.05. The most
striking were DEFA5 and DEFA6, encoding microbicidal
defensins involved in host defense, which consistently
showed increased expression in the >100 adenoma
group. It is not clear if this reflects a host or an environ-
mental difference and will require further study.
Conclusions
In conclusion, a distinct gene expression signature can
be identified in FAP vs. AFAP patients that, in turn, can
be applied to diagnostics. A separate set of genes can
also distinguish colonic phenotypic classes of individuals
with the identical APC mutation and may suggest sec-
ondary factors that modify the phenotypic penetrance in
AFAP. * Correspondence: deb.neklason@hci.utah.edu
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